Stammzellenforschung...Pluristem...PSTI... - 500 Beiträge pro Seite
eröffnet am 03.04.08 19:37:15 von
neuester Beitrag 14.04.08 16:41:42 von
neuester Beitrag 14.04.08 16:41:42 von
Beiträge: 8
ID: 1.140.095
ID: 1.140.095
Aufrufe heute: 0
Gesamt: 2.253
Gesamt: 2.253
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 38 Minuten | 17017 | |
| vor 59 Minuten | 3394 | |
| vor 46 Minuten | 3030 | |
| vor 45 Minuten | 2370 | |
| vor 39 Minuten | 1501 | |
| heute 13:29 | 1314 | |
| vor 1 Stunde | 1128 | |
| vor 40 Minuten | 897 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.109,71 | -0,29 | 224 | |||
| 2. | 2. | 166,32 | +14,96 | 204 | |||
| 3. | 8. | 9,5750 | -34,01 | 175 | |||
| 4. | 3. | 0,1905 | -0,26 | 40 | |||
| 5. | 5. | 0,0160 | -48,88 | 39 | |||
| 6. | 9. | 789,09 | +3,57 | 38 | |||
| 7. | 12. | 19,370 | -0,72 | 30 | |||
| 8. | 10. | 7,1100 | -1,66 | 28 |
Feedback
Wenn heute die Diskussion um Stammzellen stocks geht, möchte ich mal meinen Zock präsentieren: PSTI...Pluristem
www.pluristem.com
Kommt von 28 Dollar, ist jetzt bei 2,20 Dollar.
Bei guten Meldungnen sollten da doch 50 - 200% drin sein...Marketcap 11 Millionen zur Zeit...da ist noch Luft nach oben...
Hier mal eine der letzten Meldungen:
Press Release Source: Pluristem Therapeutics, Inc.
Pluristem Submits Pre-IND Application in Germany to Initiate Clinical Trials of PLX-PAD for Peripheral Artery Disease
Tuesday March 4, 8:00 am ET
NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics, Inc. (NASDAQ: PSTI - News) announced today that it has filed a Pre-Investigational New Drug (Pre-IND) application with the Paul Ehrlich Institute (PEI) in Germany for PLX-PAD, the Company’s product for the treatment of Peripheral Artery Disease. The PEI is the German federal authority granting clinical trial approvals. PLX-PAD are mesenchymal stromal cells (MSCs) obtained from the placenta and expanded using Pluristem’s proprietary 3D PluriX™ technology.
ADVERTISEMENT
Pluristem has submitted a scientific package to the PEI. The package contains the results of a proof of concept study and preclinical study synopses utilizing PLX-PAD to support an IMPD (Investigational Medicinal Product Dossier) submission planned for later this year. This Pre-IND document also contains information concerning the process used to manufacture Pluristem’s PLX-PAD product and the proposed clinical trial supporting the Company’s IMPD.
Zami Aberman, Pluristem’s President & CEO, stated: “I am proud that our team has accomplished this important milestone in submitting this Pre-IND document as planned. I believe it represents the Pluristem team’s ability and devotion to successfully meet the Company’s goal of building a pipeline of PLX products, leading the Company to future achievements and prosperity."
About Pluristem
Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells.
The placental cells are expanded in the Company’s proprietary PluriX™ 3D bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors, or other exogenous materials. Pluristem believes the resultant PLX (PLacental eXpanded) cells are multi-potent, and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to their secretion of cytokines or other potent immune modulators. Furthermore, the PLX cells are immune-privileged and immunosuppressive, hence protecting the recipient from immunological reactions that often accompany transplantations.
Pluristem’s PLX-PAD is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). Pluristem has previously announced its PLX cells can be therapeutically beneficial in the treatment of a variety of other indications, such as ischemic stroke and Parkinson’s disease (PD).
The Company’s PLX-I is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (UCB).
Pluristem has offices in the USA with research and manufacturing facilities in Israel.
www.pluristem.com
Kommt von 28 Dollar, ist jetzt bei 2,20 Dollar.
Bei guten Meldungnen sollten da doch 50 - 200% drin sein...Marketcap 11 Millionen zur Zeit...da ist noch Luft nach oben...
Hier mal eine der letzten Meldungen:
Press Release Source: Pluristem Therapeutics, Inc.
Pluristem Submits Pre-IND Application in Germany to Initiate Clinical Trials of PLX-PAD for Peripheral Artery Disease
Tuesday March 4, 8:00 am ET
NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics, Inc. (NASDAQ: PSTI - News) announced today that it has filed a Pre-Investigational New Drug (Pre-IND) application with the Paul Ehrlich Institute (PEI) in Germany for PLX-PAD, the Company’s product for the treatment of Peripheral Artery Disease. The PEI is the German federal authority granting clinical trial approvals. PLX-PAD are mesenchymal stromal cells (MSCs) obtained from the placenta and expanded using Pluristem’s proprietary 3D PluriX™ technology.
ADVERTISEMENT
Pluristem has submitted a scientific package to the PEI. The package contains the results of a proof of concept study and preclinical study synopses utilizing PLX-PAD to support an IMPD (Investigational Medicinal Product Dossier) submission planned for later this year. This Pre-IND document also contains information concerning the process used to manufacture Pluristem’s PLX-PAD product and the proposed clinical trial supporting the Company’s IMPD.
Zami Aberman, Pluristem’s President & CEO, stated: “I am proud that our team has accomplished this important milestone in submitting this Pre-IND document as planned. I believe it represents the Pluristem team’s ability and devotion to successfully meet the Company’s goal of building a pipeline of PLX products, leading the Company to future achievements and prosperity."
About Pluristem
Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells.
The placental cells are expanded in the Company’s proprietary PluriX™ 3D bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors, or other exogenous materials. Pluristem believes the resultant PLX (PLacental eXpanded) cells are multi-potent, and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to their secretion of cytokines or other potent immune modulators. Furthermore, the PLX cells are immune-privileged and immunosuppressive, hence protecting the recipient from immunological reactions that often accompany transplantations.
Pluristem’s PLX-PAD is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). Pluristem has previously announced its PLX cells can be therapeutically beneficial in the treatment of a variety of other indications, such as ischemic stroke and Parkinson’s disease (PD).
The Company’s PLX-I is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (UCB).
Pluristem has offices in the USA with research and manufacturing facilities in Israel.
Klassischer Fall eines sterbenden Biotechs.
Cash ist verbrannt (3,8$ Mios noch) und Stammzellen, jedenfalls wenn man wie zB. Geron Corp keine Alternativen hat, ist ohne Erfolg ne gaaanz kurzlebige Sache.
Kann man, wie der Wert aus Deinem anderen Thread, nicht empfehlen.
Cash ist verbrannt (3,8$ Mios noch) und Stammzellen, jedenfalls wenn man wie zB. Geron Corp keine Alternativen hat, ist ohne Erfolg ne gaaanz kurzlebige Sache.
Kann man, wie der Wert aus Deinem anderen Thread, nicht empfehlen.
Ich hoffe mal, dass sie Erfolge bringen werden und weitere Finanzierungen bekommen...Das ist für mich ein Top oder Flop Play mit geringem Einsatz...
Super! Plus 25Pluristem’s Second Pre-Clinical Study in Ischemic Stroke Shows
Statistically Significant Advantages in Functional and Anatomical Recovery
NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NASDAQ: PSTI; DAX: PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced today that the results from Fraunhofer Institute’s additional pre-clinical study utilizing the Company’s proprietary PLacental eXpanded (PLX) cells in treating ischemic stroke showed statistical significance utilizing functional as well as anatomical endpoints. PLX cells are mesenchymal stromal cells (MSCs) obtained from the placenta and expanded using Pluristem’s proprietary 3D PluriX™ technology.
Fraunhofer Institute’s scientists systemically injected PLX cells into spontaneously hypertensive rats that had undergone middle cerebral artery occlusion, a commonly accepted ischemic stroke model. The functional endpoints of improvement in beam walking and neurological severity score and the anatomical endpoint of reduction in infarct size reached statistical significance versus controls.
Zami Aberman, Pluristem’s President and CEO said: “We are very excited about the results and believe that utilizing our PLX product may successfully treat millions of ischemic stroke patients and lead to a multi-billion dollar market. This independent study, together with the previously announced favorable pre-clinical results of PLX cells to treat limb ischemia and blood cancer, give us a robust pipe line for developing new therapeutic products.”
The trial was conducted under the supervision of Professor Frank Emmrich, Head of the Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany, a branch of the Fraunhofer Society.
Prof. Frank Emmrich stated, "PLX cells possibly show potential to become a new treatment for the functional recovery from a stroke. The data show that a double injection of PLX cells at two different time points significantly improve the functional recovery and reduce of size of the lesion compared to the control. However, these preliminary findings have to be confirmed and the running experimental series have to be completed before a final statement can be made. Additional optimization surrounding the administration of PLX cells will be required to supply clear evidence that PLX cells may help patients with ischemic stroke.”
About Ischemic stroke
Ischemic stroke accounts for approximately 90% of all stroke cases and is caused when an artery to the brain becomes blocked causing a sudden disruption of blood flow. Current estimates suggest ischemic stroke affects approximately 2 million patients annually worldwide with a large percentage dying or becoming permanently disabled. Industry leaders have estimated the potential market for treating ischemic stroke to be approximately $4 billion.
About Fraunhofer Institute for Cell Therapy and Immunology
The Fraunhofer Institute for Immunology and Cell Therapy (IZI) founded in April 2005 is member of the Fraunhofer Life Sciences Alliance. Its objective being to find solutions to specific problems at the interfaces between medicine, life sciences and engineering for partners active in medicine-related industries and businesses. The Institute’s core competencies are to be found in regenerative medicine, or more precisely in cell-therapeutic methods of regenerating non-functioning tissue and organs through to the biological substitution with tissue cultivated in vitro (tissue engineering). In order for the living organism to accept the tissues without any difficulty, it is necessary to study cellular and immunological defense and control mechanisms and take these into account during process and product development. These core competencies entail a multiplicity of tasks to be solved by new products and processes. The Institute works especially closely with hospital institutions, performing quality tests and clinical studies on their behalf. Additionally it also provides assistance in obtaining manufacturing licenses and certifications.
Fraunhofer Contact:
Dr. Wilhelm Gerdes
Telefon +49 (0) 341/355 36-130
Fax +49 (0) 341/355 36-109
wilhelm.gerdes@izi.fraunhofer.de
% heute mit guter Meldung:
Statistically Significant Advantages in Functional and Anatomical Recovery
NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NASDAQ: PSTI; DAX: PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced today that the results from Fraunhofer Institute’s additional pre-clinical study utilizing the Company’s proprietary PLacental eXpanded (PLX) cells in treating ischemic stroke showed statistical significance utilizing functional as well as anatomical endpoints. PLX cells are mesenchymal stromal cells (MSCs) obtained from the placenta and expanded using Pluristem’s proprietary 3D PluriX™ technology.
Fraunhofer Institute’s scientists systemically injected PLX cells into spontaneously hypertensive rats that had undergone middle cerebral artery occlusion, a commonly accepted ischemic stroke model. The functional endpoints of improvement in beam walking and neurological severity score and the anatomical endpoint of reduction in infarct size reached statistical significance versus controls.
Zami Aberman, Pluristem’s President and CEO said: “We are very excited about the results and believe that utilizing our PLX product may successfully treat millions of ischemic stroke patients and lead to a multi-billion dollar market. This independent study, together with the previously announced favorable pre-clinical results of PLX cells to treat limb ischemia and blood cancer, give us a robust pipe line for developing new therapeutic products.”
The trial was conducted under the supervision of Professor Frank Emmrich, Head of the Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany, a branch of the Fraunhofer Society.
Prof. Frank Emmrich stated, "PLX cells possibly show potential to become a new treatment for the functional recovery from a stroke. The data show that a double injection of PLX cells at two different time points significantly improve the functional recovery and reduce of size of the lesion compared to the control. However, these preliminary findings have to be confirmed and the running experimental series have to be completed before a final statement can be made. Additional optimization surrounding the administration of PLX cells will be required to supply clear evidence that PLX cells may help patients with ischemic stroke.”
About Ischemic stroke
Ischemic stroke accounts for approximately 90% of all stroke cases and is caused when an artery to the brain becomes blocked causing a sudden disruption of blood flow. Current estimates suggest ischemic stroke affects approximately 2 million patients annually worldwide with a large percentage dying or becoming permanently disabled. Industry leaders have estimated the potential market for treating ischemic stroke to be approximately $4 billion.
About Fraunhofer Institute for Cell Therapy and Immunology
The Fraunhofer Institute for Immunology and Cell Therapy (IZI) founded in April 2005 is member of the Fraunhofer Life Sciences Alliance. Its objective being to find solutions to specific problems at the interfaces between medicine, life sciences and engineering for partners active in medicine-related industries and businesses. The Institute’s core competencies are to be found in regenerative medicine, or more precisely in cell-therapeutic methods of regenerating non-functioning tissue and organs through to the biological substitution with tissue cultivated in vitro (tissue engineering). In order for the living organism to accept the tissues without any difficulty, it is necessary to study cellular and immunological defense and control mechanisms and take these into account during process and product development. These core competencies entail a multiplicity of tasks to be solved by new products and processes. The Institute works especially closely with hospital institutions, performing quality tests and clinical studies on their behalf. Additionally it also provides assistance in obtaining manufacturing licenses and certifications.
Fraunhofer Contact:
Dr. Wilhelm Gerdes
Telefon +49 (0) 341/355 36-130
Fax +49 (0) 341/355 36-109
wilhelm.gerdes@izi.fraunhofer.de
% heute mit guter Meldung:
Jetzt plus 36% , Ja!!
Trading Spotlight
Hat sich wohl gelohnt...von 2 auf 5 Dollar an einem Tag...
hallo,
hier mal auf "deutsch"
NEW YORK - (BUSINESS WIRE) - Pluristem Therapeutics Inc. (NASDAQ: PSTI; DAX: PJT), ein Bio-Therapeutika Unternehmen spezialisiert auf die Vermarktung von Nicht-personalisiert (allogen) Zelltherapie-Produkte für eine Vielzahl von degenerativen, ischämischen Und Autoimmunerkrankungen Indikationen, hat heute bekannt gegeben, dass die Ergebnisse des Fraunhofer-Instituts zusätzliche prä-klinischen Studie nutzt das Unternehmen die proprietäre PLacental eXpanded (PLX) Zellen in der Behandlung von ischämischen Schlaganfall zeigte statistische Signifikanz Nutzung funktionale als auch anatomische Endpunkte. PLX-Zellen sind mesenchymale Stromazellen (MSCs) aus der Plazenta und erweitert mit Pluristem's proprietären 3D PluriX ™ Technologie.
Fraunhofer-Institut Wissenschaftler systemisch injiziert PLX Zellen in spontan hypertensiven Ratten, die sich Mitte Arteria cerebri Okklusion, eine allgemein anerkannte ischämischen Schlaganfall-Modell. Die funktionelle Endpunkte der Verbesserung der Strahlqualität Wander-und neurologische Schweregrad der Gäste und der anatomischen Endpunkt der Verringerung der Infarkt Größe erreicht statistische Signifikanz versus Kontrollen.
Zami Aberman, Pluristem's President und CEO, sagte: "Wir sind sehr begeistert über die Ergebnisse und glauben, dass die Nutzung unseres Produktes können PLX erfolgreich behandeln Millionen von ischämischen Schlaganfall-Patienten und führen zu einer Multi-Milliarden-Dollar-Markt. Diese unabhängige Studie, zusammen mit dem zuvor angekündigten günstigen prä-klinischen Ergebnisse der PLX-Zellen zur Behandlung von Ischämie Leib und Blut Krebs, geben Sie uns eine robuste Rohr Linie für die Entwicklung von neuen therapeutischen Produkten. "
Die Studie wurde unter der Leitung von Prof. Dr. Frank Emmrich, Leiter des Fraunhofer-Institut für Zelltherapie und Immunologie (IZI), Leipzig, Germany, eine Niederlassung der Fraunhofer-Gesellschaft.
Prof. Dr. Frank Emmrich erklärte: "PLX Zellen möglicherweise zeigen, könnte sich durchaus eine neue Behandlung für die funktionelle Erholung von einem Schlaganfall. Die Daten zeigen, dass eine doppelte Injektion von PLX-Zellen an zwei verschiedenen Zeitpunkten erheblich verbessern die funktionelle Erholung und Reduzierung der Größe von Der Läsion im Vergleich zur Kontrolle. Allerdings sind diese vorläufigen Ergebnisse zu bestätigen und die laufende experimentelle Reihe abgeschlossen sein müssen, bevor eine endgültige Aussage gemacht werden. Weitere Optimierungen rund um die Verwaltung von PLX-Zellen benötigt werden, um klare Beweise dafür, dass PLX Zellen können helfen, Patienten mit ischämischen Schlaganfall. "
Über Ischämische Schlaganfall
Ischämischen Schlaganfall Konten für ca. 90% aller Fälle, Schlaganfall und wird verursacht, wenn eine Arterie im Gehirn blockiert wird zu einer plötzlichen Unterbrechung des Blutflusses. Aktuelle Schätzungen gehen davon aus ischämischen Schlaganfall betrifft etwa 2 Millionen Patienten jährlich weltweit mit einem hohen Anteil Sterben oder dauerhaft deaktiviert werden. Branchenführer haben geschätzt, der potenzielle Markt für die Behandlung von ischämischen Schlaganfall zu rund 4 Milliarden Dollar.
Über Fraunhofer-Institut für Zelltherapie und Immunologie
Das Fraunhofer-Institut für Zelltherapie und Immunologie (IZI) im April 2005 gegründet, ist Mitglied der Fraunhofer-Allianz Life Sciences. Sein Ziel ist die Suche nach Lösungen für spezifische Probleme an den Schnittstellen von Medizin, Biowissenschaften und Ingenieurwissenschaften für die Partner aktiv in der Medizin-verwandten Branchen und Unternehmen. Die Kernkompetenzen des Instituts sind zu finden in der Regenerativen Medizin, oder genauer gesagt in Zelle-therapeutischen Methoden für die Regeneration nicht funktionierenden Gewebe und Organe bis hin zum biologischen Ersatz mit kultivierten in vitro-Gewebe (Tissue Engineering). Um für den lebenden Organismus zu akzeptieren, das Gewebe ohne jegliche Schwierigkeiten, ist es notwendig zu untersuchen zelluläre und immunologische Abwehr-und Kontrollmechanismen und diese berücksichtigen während Prozess-und Produktentwicklung. Die Kernkompetenzen beinhalten eine Vielzahl von Aufgaben zu lösen, indem neue Produkte und Prozesse. Das Institut arbeitet besonders eng mit der Krankenhaus-Institutionen, die Qualität der Durchführung klinischer Studien und Tests auf ihren Namen. Zusätzlich bietet es auch Unterstützung, um die Herstellung von Lizenzen und Zertifikate.
Arabisch nach EnglischChinesisch nach EnglischChinesisch (traditionell nach vereinfacht)Chinesisch (vereinfacht nach traditionell)Deutsch nach EnglischDeutsch nach FranzösischEnglisch nach ArabischEnglisch nach Chinesisch (traditionell)Englisch nach Chinesisch (vereinfacht)Englisch nach DeutschEnglisch nach FranzösischEnglisch nach GriechischEnglisch nach ItalienischEnglisch nach JapanischEnglisch nach KoreanischEnglisch nach NiederländischEnglisch nach PortugiesischEnglisch nach RussischEnglisch nach SpanischFranzösisch nach DeutschFranzösisch nach EnglischGriechisch nach EnglischItalienisch nach EnglischJapanisch nach EnglischKoreanisch nach EnglischNiederländisch nach EnglischPortugiesisch nach EnglischRussisch nach EnglischSpanisch nach Englisch
hier mal auf "deutsch"
NEW YORK - (BUSINESS WIRE) - Pluristem Therapeutics Inc. (NASDAQ: PSTI; DAX: PJT), ein Bio-Therapeutika Unternehmen spezialisiert auf die Vermarktung von Nicht-personalisiert (allogen) Zelltherapie-Produkte für eine Vielzahl von degenerativen, ischämischen Und Autoimmunerkrankungen Indikationen, hat heute bekannt gegeben, dass die Ergebnisse des Fraunhofer-Instituts zusätzliche prä-klinischen Studie nutzt das Unternehmen die proprietäre PLacental eXpanded (PLX) Zellen in der Behandlung von ischämischen Schlaganfall zeigte statistische Signifikanz Nutzung funktionale als auch anatomische Endpunkte. PLX-Zellen sind mesenchymale Stromazellen (MSCs) aus der Plazenta und erweitert mit Pluristem's proprietären 3D PluriX ™ Technologie.
Fraunhofer-Institut Wissenschaftler systemisch injiziert PLX Zellen in spontan hypertensiven Ratten, die sich Mitte Arteria cerebri Okklusion, eine allgemein anerkannte ischämischen Schlaganfall-Modell. Die funktionelle Endpunkte der Verbesserung der Strahlqualität Wander-und neurologische Schweregrad der Gäste und der anatomischen Endpunkt der Verringerung der Infarkt Größe erreicht statistische Signifikanz versus Kontrollen.
Zami Aberman, Pluristem's President und CEO, sagte: "Wir sind sehr begeistert über die Ergebnisse und glauben, dass die Nutzung unseres Produktes können PLX erfolgreich behandeln Millionen von ischämischen Schlaganfall-Patienten und führen zu einer Multi-Milliarden-Dollar-Markt. Diese unabhängige Studie, zusammen mit dem zuvor angekündigten günstigen prä-klinischen Ergebnisse der PLX-Zellen zur Behandlung von Ischämie Leib und Blut Krebs, geben Sie uns eine robuste Rohr Linie für die Entwicklung von neuen therapeutischen Produkten. "
Die Studie wurde unter der Leitung von Prof. Dr. Frank Emmrich, Leiter des Fraunhofer-Institut für Zelltherapie und Immunologie (IZI), Leipzig, Germany, eine Niederlassung der Fraunhofer-Gesellschaft.
Prof. Dr. Frank Emmrich erklärte: "PLX Zellen möglicherweise zeigen, könnte sich durchaus eine neue Behandlung für die funktionelle Erholung von einem Schlaganfall. Die Daten zeigen, dass eine doppelte Injektion von PLX-Zellen an zwei verschiedenen Zeitpunkten erheblich verbessern die funktionelle Erholung und Reduzierung der Größe von Der Läsion im Vergleich zur Kontrolle. Allerdings sind diese vorläufigen Ergebnisse zu bestätigen und die laufende experimentelle Reihe abgeschlossen sein müssen, bevor eine endgültige Aussage gemacht werden. Weitere Optimierungen rund um die Verwaltung von PLX-Zellen benötigt werden, um klare Beweise dafür, dass PLX Zellen können helfen, Patienten mit ischämischen Schlaganfall. "
Über Ischämische Schlaganfall
Ischämischen Schlaganfall Konten für ca. 90% aller Fälle, Schlaganfall und wird verursacht, wenn eine Arterie im Gehirn blockiert wird zu einer plötzlichen Unterbrechung des Blutflusses. Aktuelle Schätzungen gehen davon aus ischämischen Schlaganfall betrifft etwa 2 Millionen Patienten jährlich weltweit mit einem hohen Anteil Sterben oder dauerhaft deaktiviert werden. Branchenführer haben geschätzt, der potenzielle Markt für die Behandlung von ischämischen Schlaganfall zu rund 4 Milliarden Dollar.
Über Fraunhofer-Institut für Zelltherapie und Immunologie
Das Fraunhofer-Institut für Zelltherapie und Immunologie (IZI) im April 2005 gegründet, ist Mitglied der Fraunhofer-Allianz Life Sciences. Sein Ziel ist die Suche nach Lösungen für spezifische Probleme an den Schnittstellen von Medizin, Biowissenschaften und Ingenieurwissenschaften für die Partner aktiv in der Medizin-verwandten Branchen und Unternehmen. Die Kernkompetenzen des Instituts sind zu finden in der Regenerativen Medizin, oder genauer gesagt in Zelle-therapeutischen Methoden für die Regeneration nicht funktionierenden Gewebe und Organe bis hin zum biologischen Ersatz mit kultivierten in vitro-Gewebe (Tissue Engineering). Um für den lebenden Organismus zu akzeptieren, das Gewebe ohne jegliche Schwierigkeiten, ist es notwendig zu untersuchen zelluläre und immunologische Abwehr-und Kontrollmechanismen und diese berücksichtigen während Prozess-und Produktentwicklung. Die Kernkompetenzen beinhalten eine Vielzahl von Aufgaben zu lösen, indem neue Produkte und Prozesse. Das Institut arbeitet besonders eng mit der Krankenhaus-Institutionen, die Qualität der Durchführung klinischer Studien und Tests auf ihren Namen. Zusätzlich bietet es auch Unterstützung, um die Herstellung von Lizenzen und Zertifikate.
Arabisch nach EnglischChinesisch nach EnglischChinesisch (traditionell nach vereinfacht)Chinesisch (vereinfacht nach traditionell)Deutsch nach EnglischDeutsch nach FranzösischEnglisch nach ArabischEnglisch nach Chinesisch (traditionell)Englisch nach Chinesisch (vereinfacht)Englisch nach DeutschEnglisch nach FranzösischEnglisch nach GriechischEnglisch nach ItalienischEnglisch nach JapanischEnglisch nach KoreanischEnglisch nach NiederländischEnglisch nach PortugiesischEnglisch nach RussischEnglisch nach SpanischFranzösisch nach DeutschFranzösisch nach EnglischGriechisch nach EnglischItalienisch nach EnglischJapanisch nach EnglischKoreanisch nach EnglischNiederländisch nach EnglischPortugiesisch nach EnglischRussisch nach EnglischSpanisch nach Englisch
Und wieder Gute News, die zweite in 10 Tagen...
endlich nach der monatelangen Stille...
Press Release Source: Pluristem Therapeutics Inc.
Pluristem's PLX Cells Show a Statistically Significant Advantage in a Pre-Clinical Study in the Multiple Sclerosis Model
Monday April 14, 10:00 am ET
NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NASDAQ:PSTI - News) (DAX:PJT) a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced today that a preclinical study utilizing the Company’s PLacental eXpanded (PLX) cells showed a statistically significant advantage in ameliorating functional deficiencies in a standard Multiple Sclerosis (MS) animal model. PLX cells are mesenchymal stromal cells (MSCs) obtained from the placenta and expanded using Pluristem’s proprietary 3D PluriX™ technology.
ADVERTISEMENT
Researchers at Pluristem utilized the Experimental Autoimmune Encephalitis (EAE) animal model for the study, the paradigm for MS in humans. After EAE was induced, a number of the animals were given PLX cells intravenously while the remaining served as a control. There was a significant reduction in the EAE score in those animals given PLX cells versus the control group and this beneficial effect was seen throughout the 25-day duration of the study. The EAE score is a measurement of functional outcomes in the EAE-afflicted animal and correlates closely with a histological improvement in EAE-induced lesions. Additionally, the beneficial effects were similar to when Zappia et. al. used MSCs that were non-placental in origin in this EAE animal model†.
Zami Aberman, Pluristem’s President and CEO said: “We are very excited that our PLX cells were able to demonstrate beneficial results that are statistically significant in this standardized model for Multiple Sclerosis. These results, in addition to our previously announced PLX STROKE results, demonstrate that PLX cells may be useful in the treatment of central nervous system (CNS) disorders and potentially help millions of people. Additionally, we believe this experiment demonstrates we can potentially utilize our off-the-shelf, easy to obtain PLX cells and achieve results that are as good as or better than MSCs obtained from other more difficult to find sources.”
†Zappia et. al. Mesenchymal stem cells ameliorate experimental autoimmune encephalitis inducing T cell anergy. Blood. 2005;106: 1755-1761
About Multiple Sclerosis (MS)
Multiple sclerosis (MS), also known as disseminated sclerosis or encephalomyelitis disseminate, is an autoimmune condition in which the immune system attacks the central nervous system (CNS), leading to demyelination. Myelin is the insulating sheath that surrounds nerve cells (neurons). MS may cause numerous physical and mental symptoms, and often progresses to physical and cognitive disability. The World Health Organization (WHO) estimates that over 2.5 million people globally suffer from MS, which represents a current market of approximately $5.4 billion for disease-modifying agents to treat the disorder.
About Pluristem
Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial, non-embryonic, adult stem cell source.
These placental mesenchymal stromal cells (MSCs) are expanded in the Company’s proprietary PluriX™ 3D bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. Pluristem believes the resultant PLX (PLacental eXpanded) cells are multi-potent and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune privileged and have immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.
Pluristem’s first product, PLX-PAD, is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). The Company’s PLX-I product is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (UCB). PLX-STROKE shows potential to become a new treatment for the functional recovery from an ischemic stroke.
Pluristem has offices in the USA with research and manufacturing facilities in Israel. www.pluristem.com
See our product animation on YouTube: http://www.youtube.com/watch?v=OFhWXyJT6Us
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, when we say that the Company’s PLacental eXpanded (PLX) cells showed a statistically significant advantage in ameliorating functional deficiencies in a standard Multiple Sclerosis (MS) animal model; that these results, in addition to our previously announced PLX STROKE results, demonstrate that PLX cells may be useful in the treatment of central nervous system (CNS) disorders and potentially help millions of people; that we believe this experiment demonstrates we can potentially utilize our off-the-shelf, easy to obtain PLX cells and achieve results that are as good as or better than MSCs obtained from other more difficult to find sources, we are using forward looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
Contact:
Pluristem Therapeutics Inc.
Investor Contact:
William Prather RPh, MD, Sr. VP Corporate Development
303-883-4954
bill@pluristem.com
--------------------------------------------------------------------------------
endlich nach der monatelangen Stille...
Press Release Source: Pluristem Therapeutics Inc.
Pluristem's PLX Cells Show a Statistically Significant Advantage in a Pre-Clinical Study in the Multiple Sclerosis Model
Monday April 14, 10:00 am ET
NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NASDAQ:PSTI - News) (DAX:PJT) a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced today that a preclinical study utilizing the Company’s PLacental eXpanded (PLX) cells showed a statistically significant advantage in ameliorating functional deficiencies in a standard Multiple Sclerosis (MS) animal model. PLX cells are mesenchymal stromal cells (MSCs) obtained from the placenta and expanded using Pluristem’s proprietary 3D PluriX™ technology.
ADVERTISEMENT
Researchers at Pluristem utilized the Experimental Autoimmune Encephalitis (EAE) animal model for the study, the paradigm for MS in humans. After EAE was induced, a number of the animals were given PLX cells intravenously while the remaining served as a control. There was a significant reduction in the EAE score in those animals given PLX cells versus the control group and this beneficial effect was seen throughout the 25-day duration of the study. The EAE score is a measurement of functional outcomes in the EAE-afflicted animal and correlates closely with a histological improvement in EAE-induced lesions. Additionally, the beneficial effects were similar to when Zappia et. al. used MSCs that were non-placental in origin in this EAE animal model†.
Zami Aberman, Pluristem’s President and CEO said: “We are very excited that our PLX cells were able to demonstrate beneficial results that are statistically significant in this standardized model for Multiple Sclerosis. These results, in addition to our previously announced PLX STROKE results, demonstrate that PLX cells may be useful in the treatment of central nervous system (CNS) disorders and potentially help millions of people. Additionally, we believe this experiment demonstrates we can potentially utilize our off-the-shelf, easy to obtain PLX cells and achieve results that are as good as or better than MSCs obtained from other more difficult to find sources.”
†Zappia et. al. Mesenchymal stem cells ameliorate experimental autoimmune encephalitis inducing T cell anergy. Blood. 2005;106: 1755-1761
About Multiple Sclerosis (MS)
Multiple sclerosis (MS), also known as disseminated sclerosis or encephalomyelitis disseminate, is an autoimmune condition in which the immune system attacks the central nervous system (CNS), leading to demyelination. Myelin is the insulating sheath that surrounds nerve cells (neurons). MS may cause numerous physical and mental symptoms, and often progresses to physical and cognitive disability. The World Health Organization (WHO) estimates that over 2.5 million people globally suffer from MS, which represents a current market of approximately $5.4 billion for disease-modifying agents to treat the disorder.
About Pluristem
Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial, non-embryonic, adult stem cell source.
These placental mesenchymal stromal cells (MSCs) are expanded in the Company’s proprietary PluriX™ 3D bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. Pluristem believes the resultant PLX (PLacental eXpanded) cells are multi-potent and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune privileged and have immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.
Pluristem’s first product, PLX-PAD, is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). The Company’s PLX-I product is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (UCB). PLX-STROKE shows potential to become a new treatment for the functional recovery from an ischemic stroke.
Pluristem has offices in the USA with research and manufacturing facilities in Israel. www.pluristem.com
See our product animation on YouTube: http://www.youtube.com/watch?v=OFhWXyJT6Us
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, when we say that the Company’s PLacental eXpanded (PLX) cells showed a statistically significant advantage in ameliorating functional deficiencies in a standard Multiple Sclerosis (MS) animal model; that these results, in addition to our previously announced PLX STROKE results, demonstrate that PLX cells may be useful in the treatment of central nervous system (CNS) disorders and potentially help millions of people; that we believe this experiment demonstrates we can potentially utilize our off-the-shelf, easy to obtain PLX cells and achieve results that are as good as or better than MSCs obtained from other more difficult to find sources, we are using forward looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
Contact:
Pluristem Therapeutics Inc.
Investor Contact:
William Prather RPh, MD, Sr. VP Corporate Development
303-883-4954
bill@pluristem.com
--------------------------------------------------------------------------------
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 218 | ||
| 199 | ||
| 170 | ||
| 40 | ||
| 39 | ||
| 38 | ||
| 31 | ||
| 30 | ||
| 29 | ||
| 26 |
| Wertpapier | Beiträge | |
|---|---|---|
| 26 | ||
| 25 | ||
| 24 | ||
| 24 | ||
| 21 | ||
| 20 | ||
| 20 | ||
| 19 | ||
| 19 | ||
| 18 |
